靶向血管生成的抗肿瘤海洋药物的研制策略  

A strategy for developing anti-tumor marine drugs targeting angiogenesis

作　　者：张玉艳[1,2] 林秀坤[1] 牛荣丽[1] 

机构地区：[1]中国科学院海洋研究所,青岛266071 [2]中国科学院研究生院,北京100039

出　　处：《中国新药杂志》2008年第19期1644-1649,共6页Chinese Journal of New Drugs

基　　金：国家863计划专题课题(2007AA09Z408);国家863计划项目课题(2007AA091403)

摘　　要：实体瘤的生长、发育以及转移都依赖于新生血管生成提供营养,阻断肿瘤的血管生成成为新型抗肿瘤药物研究的重要方向。针对血管生成的不同生物学过程发展新型的血管生成抑制剂为肿瘤的治疗形成了新的研究领域。迄今为止,多种以血管生成为靶点的抗肿瘤药物已经在国内外上市。海洋生物是新型药物的重要分子库,由海洋生物中发现的多种血管生成抑制剂显示了独特的分子结构与作用机制。现对发现的数种海洋来源的血管生成抑制剂的作用机制进行论述,提出了研发新型抗肿瘤药物的发展战略。Angiogenesis is essential for the growth, development and translocation of solid tumors tion of angiogenesis represents a promising area for developing anti-tumor agents. Based on the different progresses of angiogenesis, various approaches have been applied to develop tumor angiogenesis inhibitors Inhibi- ological TAIs ） , and several TAIs have been on the market at home and abroad. Marine organisms, as a molecular bank for new drugs, have produced many TAIs with special structures and modes of actions. Herein, we reviewed the mechanisms of different kinds of TAIs from marine organisms, and presented a strategy for the development of new type anti-tumor medicines

关 键 词：血管生成 血管生成抑制剂 海洋药物 抗肿瘤药物 

分 类 号：R979.1[医药卫生—药品]